Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers.
Continuous glucose monitoring
Cystic fibrosis
Diabetes
OGTT
Screening
Journal
Journal of clinical & translational endocrinology
ISSN: 2214-6237
Titre abrégé: J Clin Transl Endocrinol
Pays: Netherlands
ID NLM: 101629335
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
02
11
2021
revised:
12
03
2022
accepted:
31
03
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
19
4
2022
Statut:
epublish
Résumé
This study aimed to analyze clinical practices concerning cystic fibrosis-related diabetes (CFRD) screening in France. A web-based questionnaire was distributed between December 1, 2020 and January 31, 2021 among 47 cystic fibrosis centers including pediatric, adult, and mixed units. In accordance with guidelines, 92.8% of CF centers performed annual oral glucose tolerance tests (OGTT). Overall, 86.3% of CF centers performed 1- and 2-hour blood glucose determinations following OGTT. The OGTT was conducted before 10 years of age in 73% of pediatric centers. Continuous glucose monitoring (CGM) and laboratory glycated hemoglobin were employed for CFRD screening in 86.5% and 50% of centers, respectively. CGM was carried out in 69% of centers after glucose tolerance abnormalities had been detected in OGTT. Most CF centers used OGTT and CGM for CFRD screening. Studies are required to assess CGM usefulness as a validated tool in CFRD screening.
Identifiants
pubmed: 35433271
doi: 10.1016/j.jcte.2022.100298
pii: S2214-6237(22)00006-0
pmc: PMC9010626
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100298Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Cyst Fibros. 2016 Jan;15(1):127-32
pubmed: 25818059
PLoS One. 2021 Mar 18;16(3):e0246897
pubmed: 33735186
J Cyst Fibros. 2021 Sep;20(5):725-726
pubmed: 34364815
J Cyst Fibros. 2021 Sep;20(5):803-809
pubmed: 33353861
Diabetes Care. 2010 Dec;33(12):2697-708
pubmed: 21115772
Diabetes Care. 2011 Feb;34(2):292-5
pubmed: 21228248
J Cyst Fibros. 2021 Sep;20(5):779-784
pubmed: 33478894
J Cyst Fibros. 2014 Jul;13(4):478-84
pubmed: 24359972
Pediatr Diabetes. 2018 Oct;19 Suppl 27:64-74
pubmed: 30094886
J Cyst Fibros. 2020 Mar;19(2):305-309
pubmed: 31126898
J Cyst Fibros. 2020 Mar;19(2):321-327
pubmed: 31680042
Diabetes Care. 2018 Jul;41(7):1406-1413
pubmed: 29674323
J Cyst Fibros. 2019 Oct;18 Suppl 2:S25-S31
pubmed: 31679725
J Cyst Fibros. 2018 Nov;17(6):783-790
pubmed: 29580828
PLoS One. 2021 Apr 21;16(4):e0250036
pubmed: 33882078
Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):891-5
pubmed: 10988101